Trial · NCT00586820
Role of Endothelin in Microvascular Dysfunction Following PCI for NSTEMI
NCT00586820, Phase 2, Completed, Mayo Clinic; results first posted 2014-07-04
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Role of Endothelin in Microvascular Dysfunction Following PCI for NSTEMI. Trials, record NCT00586820. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00586820
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Role of Endothelin in Microvascular Dysfunction Following PCI for NSTEMI
- NCT number
- NCT00586820
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 23 participants, actual
- Lead sponsor
- Mayo Clinic
- Conditions
- Myocardial Reperfusion Injury
- Interventions
- BQ-123, Placebo
- First posted
- 2008-01-07
- Last updated
- 2014-07-04
- Results first posted
- 2014-07-04
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Average Peak Velocity (APV) Immediately Following Percutaneous Coronary Intervention (PCI) | immediately following PCI procedure | Coronary microvascular blood flow will be assessed following successful PCI by measuring APV in the culprit vessel using Doppler echocardiography. |
| Secondary | Percent Change in Creatinine Kinase Isoenzyme Muscle/Brain Type (CK-MB) From Immediately Pre-PCI to 8 and 16 Hours Post-PCI | immediately pre-PCI, 8 hours post-PCI, 16 hours post-PCI | CK-MB is a cardiac marker that can demonstrate the development of heart muscle necrosis resulting from an acute interruption of blood supply to a part of the heart. CK-MB is measured by a blood test. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Average Peak Velocity (APV) Immediately Following Percutaneous Coronary Intervention (PCI) | immediately following PCI procedure | One subject on the BQ-123 arm was excluded from the analysis due to unsuccessful PCI. | cm/s | MEDIAN |
| SECONDARY | Percent Change in Creatinine Kinase Isoenzyme Muscle/Brain Type (CK-MB) From Immediately Pre-PCI to 8 and 16 Hours Post-PCI | immediately pre-PCI, 8 hours post-PCI, 16 hours post-PCI | One subject on the BQ-123 arm was excluded from the analysis due to unsuccessful PCI. | percent change | MEDIAN |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Average Peak Velocity (APV) Immediately Following Percutaneous Coronary Intervention (PCI) | BQ-123 | 30 | Inter-Quartile Range 20 to 37 | cm/s | |
| Average Peak Velocity (APV) Immediately Following Percutaneous Coronary Intervention (PCI) | Placebo | 19 | Inter-Quartile Range 9 to 26 | cm/s | |
| Percent Change in Creatinine Kinase Isoenzyme Muscle/Brain Type (CK-MB) From Immediately Pre-PCI to 8 and 16 Hours Post-PCI | BQ-123 | % Change immediate pre-PCI, 8 hr post-PCI | -17 | Inter-Quartile Range -26 to -10 | percent change |
| Percent Change in Creatinine Kinase Isoenzyme Muscle/Brain Type (CK-MB) From Immediately Pre-PCI to 8 and 16 Hours Post-PCI | Placebo | % Change immediate pre-PCI, 8 hr post-PCI | 26 | Inter-Quartile Range -15 to 134 | percent change |
| Percent Change in Creatinine Kinase Isoenzyme Muscle/Brain Type (CK-MB) From Immediately Pre-PCI to 8 and 16 Hours Post-PCI | BQ-123 | % Change immediate pre-PCI, 16 hr post-PCI | -17 | Inter-Quartile Range -38 to 14 | percent change |
| Percent Change in Creatinine Kinase Isoenzyme Muscle/Brain Type (CK-MB) From Immediately Pre-PCI to 8 and 16 Hours Post-PCI | Placebo | % Change immediate pre-PCI, 16 hr post-PCI | 107 | Inter-Quartile Range 2 to 446 | percent change |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | BQ-123 | 12 | |
| Overall Study | STARTED | Placebo | 11 | |
| Overall Study | COMPLETED | BQ-123 | 11 | |
| Overall Study | COMPLETED | Placebo | 11 | |
| Overall Study | NOT COMPLETED | BQ-123 | 1 | |
| Overall Study | NOT COMPLETED | Placebo | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | BQ-123 | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | BQ-123 | 0 | 12 |
| Total, other adverse events | Placebo | 0 | 11 |
| Total, serious adverse events | BQ-123 | 0 | 12 |
| Total, serious adverse events | Placebo | 0 | 11 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 27547429 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| BQ-123 vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00586820
GET https://conductscience.org/api/trials/v1/NCT00586820/registered